Abstract CT065: Modakafusp alfa shows intratumoral immune pharmacodynamics (PD) in a subset of patients (pts) in a phase 1b study in advanced/metastatic solid tumors
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct065
Abstract: Background: Modakafusp alfa (moda), a novel immunocytokine, is an innate immune enhancer comprising an anti-CD38 IgG4 antibody fused to 2 attenuated interferon (IFN) α2b molecules. Moda is being evaluated in phase 1/2 trials for multiple… read more here.
Keywords: modakafusp alfa; solid tumors; response; tumor ... See more keywords
Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198119
Abstract: Modakafusp alfa is a first-in-class immunocytokine directing interferon-α to CD38-positive cells. In our previously reported phase 1/2 trial, the maximum tolerated dose of modakafusp alfa in patients with RRMM was 3 mg/kg every 4 weeks… read more here.
Keywords: 120 cohort; cohort; modakafusp alfa; 240 cohort ... See more keywords